Tag

One of Israel’s leading businessmen and a shareholder in Perrigo Pharmaceuticals will next week vote against a $27 billion offer for the company from generic drugmaker Mylan Inc, saying the price is too low. The way he sees it, if the transaction doesn’t go through...

Teva will pay $33.75 billion in cash and $6.75 billion in shares, representing a 10 percent stake in the Israel-based company, Teva said. Teva wants to bulk up its core generics business to help cope with stagnating drug prices and a decline in the supply of its raw material,...